Bone Quality Evolution in Medication-Related Osteonecrosis of the Jaw Assessed by CBCT (B-ONJ EVOL)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNantes University Hospital
About this trial
Medication-related osteonecrosis of the jaw (MRONJ) is a known complication of antiresorptive therapies such as bisphosphonates and denosumab. It can lead to bone damage in the jaw, with variable clinical outcomes depending on disease stage and management.
Cone Beam Computed Tomography (CBCT) is currently recommended for diagnosis and follow-up of MRONJ. However, most studies rely on qualitative or descriptive imaging findings, and little is known about how bone quality evolves over time using quantitative imaging parameters.
This retrospective multicenter study aims to describe the evolution of bone quality in patients with MRONJ using CBCT imaging. Bone parameters such as bone mineral density and trabecular structure will be measured at diagnosis and during follow-up.
The study will help improve understanding of bone changes over time in MRONJ and may contribute to better assessment and management of the disease.
Eligibility criteria
Qualifiers
Adult patient aged 18 years or older
Diagnosis of medication-related osteonecrosis of the jaw (MRONJ), stage 0, 1, or 2
Available diagnostic CBCT and at least 2 follow-up cone beam computed tomography (CBCT) examinations
Able to understand the study information and not opposed to participation
Disqualifiers
Other jaw bone disease
History of cervicofacial irradiation
Stage 3 medication-related osteonecrosis of the jaw
Fewer than 2 follow-up cone beam computed tomography (CBCT) examinations
Trial design
Treatments tested in this trial
- Cone Beam Computed Tomography Imaging
Treatment groups
25 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov